NUVB vs PFE
NUVB: Nuvation Bio is a clinical-stage oncology firm advancing a portfolio of targeted small-molecule therapies for patients with solid tumors, highlighted by its ROS1-positive NSCLC treatment, IBTROZI. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | NUVB | PFE | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $4.95 | $27.82 | |
| Market cap | $1.7B | $158.6B | |
| P/E as of 2026-10-08 | n/a | 36.83 | |
| Net margin FY2025, SEC XBRL | -325.3% | +12.4% | PFE higher |
| Gross margin FY2024, SEC XBRL | +10.1% | n/a | |
| Operating margin FY2025, SEC XBRL | -338.7% | n/a | |
| ROE FY2025, SEC XBRL | -66.9% | +9.0% | PFE higher |
| ROA FY2025, SEC XBRL | -34.4% | +3.7% | PFE higher |
| Debt / equity as of 2026-09-03 | 1.63 | 0.74 | PFE lower |
| Revenue growth (YoY) as of 2026-09-03 | +1083.6% | -0.2% | NUVB higher |
| Revenue CAGR (3y) SEC XBRL | n/a | -14.8% | |
| Dividend yield as of 2026-09-02 | n/a | +6.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 11 | PFE higher |
| Beta as of 2026-09-03 | 1.45 | 0.39 | |
| 1-year return as of 2026-10-08 close | +33.1% | +8.3% | NUVB higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.